Li Jiayu, Ma Shuhan, Pei Hongdi, Jiang Jici, Zou Quan, Lv Zhibin
Student Innovation Competition Team, College of Biomedical Engineering, Sichuan University, Chengdu 610065, China.
College of Life Science, Sichuan University, Chengdu 610065, China.
Heliyon. 2023 Oct 29;9(11):e21329. doi: 10.1016/j.heliyon.2023.e21329. eCollection 2023 Nov.
T cell proliferation regulators (Tcprs), which are positive regulators that promote T cell function, have made great contributions to the development of therapies to improve T cell function. CAR (chimeric antigen receptor) -T cell therapy, a type of adoptive cell transfer therapy that targets tumor cells and enhances immune lethality, has led to significant progress in the treatment of hematologic tumors. However, the applications of CAR-T in solid tumor treatment remain limited. Therefore, in this review, we focus on the development of Tcprs for solid tumor therapy and prognostic prediction. We summarize potential strategies for targeting different Tcprs to enhance T cell proliferation and activation and inhibition of cancer progression, thereby improving the antitumor activity and persistence of CAR-T. In summary, we propose means of enhancing CAR-T cells by expressing different Tcprs, which may lead to the development of a new generation of cell therapies.
T细胞增殖调节剂(Tcprs)是促进T细胞功能的正向调节剂,为改善T细胞功能的治疗方法的发展做出了巨大贡献。嵌合抗原受体(CAR)-T细胞疗法是一种靶向肿瘤细胞并增强免疫杀伤力的过继性细胞转移疗法,在血液系统肿瘤的治疗中取得了显著进展。然而,CAR-T在实体瘤治疗中的应用仍然有限。因此,在本综述中,我们重点关注用于实体瘤治疗和预后预测的Tcprs的发展。我们总结了针对不同Tcprs的潜在策略,以增强T细胞增殖和激活以及抑制癌症进展,从而提高CAR-T的抗肿瘤活性和持久性。总之,我们提出了通过表达不同的Tcprs来增强CAR-T细胞的方法,这可能会导致新一代细胞疗法的发展。